< 生产厂家价格 >

透明质酸钠

透明质酸钠用途

Hyaluronic acid sodium salt 是由二糖的重复单元组成的生物聚合物,应用领域广泛。

点击显示

透明质酸钠名称

[ CAS 号 ]:
9067-32-7

[ 中文名 ]:
透明质酸钠

[ 英文名 ]:
Sodium Hyaluronate

[中文别名 ]:

玻璃(糖醛)酸钠

[英文别名 ]:

MFCD00875848
hyaluronic acid sodium salt
EINECS 232-678-0

透明质酸钠生物活性

[ 描述 ]:

Hyaluronic acid sodium salt 是由二糖的重复单元组成的生物聚合物,应用领域广泛。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

天然产物 >> 糖和糖苷

研究领域 >> 癌症

[体外研究]

透明质酸(HA)由于其与大量水分子的结合能力而广泛用于美容医学中。它可以改善组织水合作用和抵抗机械损伤。 HA在伤口愈合,排卵,受精,信号转导和肿瘤生理学中起重要作用。 HA用于关节疾病,例如骨关节炎或类风湿性关节炎。高分子量的HA降低炎性细胞的趋化性和迁移性,其作为炎症过程的良好屏障并且保护免受自由基的影响。 HA由于其对角膜内皮的润滑性质而用于眼科学,并且改善组织水合作用和细胞对美学皮肤病学中的机械损伤的抵抗力,并且具有边际副作用。一些试验表明其在肿瘤标志物,肝脏疾病和药物中的作用[1]。透明质酸在癌症生长和转移中起重要作用。 HA和HA片段-肿瘤细胞相互作用可激活下游信号通路,促进细胞增殖,粘附,迁移和侵袭,并诱导消化道肿瘤中的血管生成,淋巴管生成,上皮-间质转化,干细胞样特性和化学放射性[2]。。

[体内研究]

应用关节内HA的影响已在许多动物研究中得到证实。对HA的研究表明,它促进软骨基质的合成,防止其降解,减少炎症,刺激内源性HA的合成,并改善软骨的弹性和水分[1]。局部施用的高分子量HA制剂促进新鲜皮肤伤口的愈合。它们还可促进静脉性腿部溃疡的愈合,并可用于治疗慢性伤口[3]。

[参考文献]

[1]. Salwowska NM, et al. Physiochemical properties and application of hyaluronic acid: a systematic review. J Cosmet Dermatol. 2016 Dec;15(4):520-526.

[2]. Wu RL, et al. Hyaluronic acid in digestive cancers. J Cancer Res Clin Oncol. 2017 Jan;143(1):1-16.

[3]. Kogan G, et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett. 2007 Jan;29(1):17-25.

[相关活性小分子]

透明质酸钠物理化学性质

[ 密度 ]:
1.78g/cm3

[ 沸点 ]:
791.6ºC

[ 分子式 ]:
C₁₄H₂₂NNaO₁₁

[ 分子量 ]:
799.63800

[ 闪点 ]:
432.5ºC

[ 精确质量 ]:
799.22300

[ PSA ]:
399.71000

[ 外观性状 ]:
固体

[ 储存条件 ]:
−20°C

[ 稳定性 ]:
Stable. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
SOLUBLE

透明质酸钠MSDS

详细MSDS(安全技术说明书)

透明质酸钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MT7250000

CHEMICAL NAME :: Hyaluronic acid, sodium salt

CAS REGISTRY NUMBER :: 9067-32-7

LAST UPDATED :: 199612

DATA ITEMS CITED :: 18

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >800 mg/kg

TOXIC EFFECTS :: Nutritional and Gross Metabolic - other changes

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12,5369,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1770 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - effect, not otherwise specified Blood - normocytic anemia

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12,5369,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >4 gm/kg

TOXIC EFFECTS :: Behavioral - ataxia Nutritional and Gross Metabolic - other changes

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12,5369,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,849,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1500 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea Skin and Appendages - hair

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 28,1013,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >4 gm/kg

TOXIC EFFECTS :: Behavioral - ataxia Nutritional and Gross Metabolic - other changes

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12,5369,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >50 mg/kg

TOXIC EFFECTS :: Gastrointestinal - nausea or vomiting Skin and Appendages - dermatitis, other (after systemic exposure)

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19(Suppl 1),S13,1991

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,849,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 1820 mg/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - respiratory stimulation Blood - normocytic anemia

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12,5369,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure) Nutritional and Gross Metabolic - other changes

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 12,5369,1984 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2275 mg/kg/13W-I

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain Nutritional and Gross Metabolic - changes in sodium Nutritional and Gross Metabolic - changes in chlorine

REFERENCE :: KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 27,5809,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1680 mg/kg/4W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - other changes in urine composition Blood - normocytic anemia Blood - changes in leukocyte (WBC) count

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 13,2763,1985 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 189 mg/kg

SEX/DURATION :: multigenerations

TOXIC EFFECTS :: Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Newborn - sex ratio

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 29,139,1985

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 220 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 29,111,1985

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 77 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 29,111,1985

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 660 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 29,111,1985

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 91 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - ovaries, fallopian tubes

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 29,131,1985

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 52 mg/kg

SEX/DURATION :: male 91 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 28,1041,1984

点击显示

透明质酸钠安全信息

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi: Irritant;

[ 风险声明 (欧洲) ]:
36/37/38

[ 安全声明 (欧洲) ]:
22-24/25-36/37/39-27-26

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
MT7250000

[ 海关编码 ]:
3913900000

透明质酸钠合成路线

详细合成路线

透明质酸钠上下游产品

透明质酸钠上游产品

透明质酸钠下游产品

透明质酸钠制备

是透明质酸羧基与金属钠离子所成的盐。透明质酸普遍存在于动物和人体内，如皮肤、肌肉、软骨、脑、鸡冠、动脉和静脉壁等。常用提取原料有雄鸡冠、脐带、牛眼等。以鸡冠为原料的制取方法如下。

1.提取：新鲜鸡冠用丙酮洗、脱水粉碎，加蒸馏水浸泡提取24h，重复3次，合并滤液。

2.除蛋白、沉淀：提取液与等体积氯仿混合搅拌3h，分出水相，加２倍量乙醇，收集沉淀、丙酮脱水、真空干燥，得粗品透明酸。

3.再经酶解、络合、解离、沉淀得精品透明质酸。然后和金属钠离子成盐。

点击显示

透明质酸钠海关

[ 海关编码 ]: 3913900000

透明质酸钠文献

The effects of biological lubricating molecules on flexor tendon reconstruction in a canine allograft model in vivo.

Plast. Reconstr. Surg. 133(5) , 628e-637e, (2014)

Using allograft is an attractive alternative for flexor tendon reconstruction because of the lack of donor-site morbidity, and better matching to the intrasynovial environment. The purpose of this stu...

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Clin. Cancer Res. 21 , 2753-62, (2015)

CD44, a cell surface glycoprotein, plays important roles in the development, progression, and metastasis of various tumor types. The aim of this study was to investigate how the expression of CD44 iso...

Transcription of the Streptococcus pyogenes hyaluronic acid capsule biosynthesis operon is regulated by previously unknown upstream elements.

Infect. Immun. 82(12) , 5293-307, (2014)

The important human pathogen Streptococcus pyogenes (group A Streptococcus [GAS]) produces a hyaluronic acid (HA) capsule that plays critical roles in immune evasion. Previous studies showed that the ...

更多文献

透明质酸钠

透明质酸钠用途

透明质酸钠名称

透明质酸钠生物活性

透明质酸钠物理化学性质

透明质酸钠MSDS

详细MSDS(安全技术说明书)

透明质酸钠毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

透明质酸钠安全信息

透明质酸钠合成路线

详细合成路线

透明质酸钠上下游产品

透明质酸钠上游产品

透明质酸钠下游产品

透明质酸钠制备

透明质酸钠海关

透明质酸钠文献

相关化工产品/化学物质：

推荐生产厂家/供应商：

相关化合物